Evidence map›Paper›PMID 40232346›Full record

Observational studyRheumatology international2025

Demographics and clinical manifestations in patients with Behçet's disease: a retrospective observational study from a non-endemic country.

Lucija Prtenjača, Miroslav Mayer, Boris Karanović, Krešimir Rukavina, Marija Bakula, Ivan Padjen, Marija Šćepović-Ljucović, Ljiljana Smiljanić Tomičević, Branimir Anić, Marko Barešić

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lucija PrtenjačaUniversity department for Rheumatology, Physical and Rehabilitation medicine, School of Medicine, University of Zagreb, University Hospital Centre Sestre Milosrdnice, Zagreb, Croatia. lucijamilolovic93@gmail.com.ORCID http://orcid.org/0009-0007-6007-4940
Miroslav MayerDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, University of Zagreb, University Hospital Centre Zagreb, Zagreb, Croatia.ORCID http://orcid.org/0000-0001-9951-6610
Boris KaranovićDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, University of Zagreb, University Hospital Centre Zagreb, Zagreb, Croatia.ORCID http://orcid.org/0000-0002-5884-1190
Krešimir RukavinaDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, University of Zagreb, University Hospital Centre Zagreb, Zagreb, Croatia.ORCID http://orcid.org/0000-0003-1856-7382
Marija BakulaDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, University of Zagreb, University Hospital Centre Zagreb, Zagreb, Croatia.ORCID http://orcid.org/0000-0002-0176-362X
Ivan PadjenDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, University of Zagreb, University Hospital Centre Zagreb, Zagreb, Croatia.ORCID http://orcid.org/0000-0002-9249-9325
Marija Šćepović-LjucovićDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, University of Zagreb, University Hospital Centre Zagreb, Zagreb, Croatia.ORCID http://orcid.org/0000-0002-9304-9211
Ljiljana Smiljanić TomičevićDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, University of Zagreb, University Hospital Centre Zagreb, Zagreb, Croatia.ORCID http://orcid.org/0000-0003-2807-7440
Branimir AnićDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, University of Zagreb, University Hospital Centre Zagreb, Zagreb, Croatia.ORCID http://orcid.org/0000-0003-4940-0577
Marko BarešićDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, University of Zagreb, University Hospital Centre Zagreb, Zagreb, Croatia.ORCID http://orcid.org/0000-0001-6281-5705

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Behçet's disease (BD) is a systemic vasculitis of unknown origin affecting both arterial and venous vessels, resulting in diverse clinical features. Its manifestations vary due to ethnic, geographic, and individual differences. Although the highest prevalence of BD is reported along the ancient Silk Road route, nowadays, due to population migrations, the disease can be detected worldwide. Our study aimed to evaluate the demographic and clinical characteristics of patients with BD in a cohort from a non-endemic country and compare it with other cohorts from endemic and non-endemic countries worldwide. Our retrospective observational case-series study included the data from a single Rheumatology centre. We analyzed the data from 38 patients (17 men and 21 women) with a mean age at diagnosis of 29 years ± SD 8.87 and with a mean follow-up of 12.7 years. The most common manifestations were oral (97.4%) and genital ulcerations (73.7%), skin (57.9%) and ophthalmological changes (63.1%). Other clinical manifestations, musculoskeletal (42.1%), vascular (18.4%), neurological (15.8%) and gastrointestinal (15.8%) were less common. HLA-B51 frequency was 51.5%, without significant difference between females and males (10:7 cases). All patients were treated with local therapy, while systemic glucocorticoids were given in 84.2%, followed by colchicine in 44.7%. Immunosuppressive / immunomodulator therapy (most common azathioprine) was administered in 68.4% of patients. Due to disease severity, 13.2% of patients required biological TNF- inhibitor. Although BD is most prevalent in endemic countries, the disease can be diagnosed worldwide. Due to the disease's complex pathogenesis, its varied presenting manifestations, and the lack of pathognomonic signs and symptoms, diagnosis can be delayed in non-endemic countries, leading to the untimely initiation of targeted treatment.

Indexed as

Behcet SyndromeAdultFemaleHLA-B51 AntigenHumansImmunosuppressive AgentsMaleMiddle AgedPrevalenceRetrospective StudiesYoung AdultHLA-B51 AntigenImmunosuppressive AgentsBehçet's diseaseBehcet syndromeEpidemiologyOld silk route diseaseSytemic vasculitisTherapy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.